Skip to content
10-Q

Quarterly Report

PATHFINDER CELL THERAPY, INC.

0001213900-15-003765

← back to feed
Filed
May 15, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2015 · Mar 31, 2015 667.16M sh
Operating Cash Flow Q1 2015 · Mar 31, 2015 −$176K
Operating Cash Flow Q1 2015 · Mar 31, 2014 −$286K
Cash And Equivalents Q1 2015 · Mar 31, 2015 $21K
Cash And Equivalents Q1 2015 · Dec 31, 2014 $26K
Cash And Equivalents Q1 2015 · Mar 31, 2014 $66K
Cash And Equivalents Q1 2015 · Dec 31, 2013 $44K
Stockholders Equity Q1 2015 · Mar 31, 2015 −$6.22M
Stockholders Equity Q1 2015 · Dec 31, 2014 −$5.94M
Current Liabilities Q1 2015 · Mar 31, 2015 $6.31M
Current Liabilities Q1 2015 · Dec 31, 2014 $6.05M
Current Assets Q1 2015 · Mar 31, 2015 $54K
Current Assets Q1 2015 · Dec 31, 2014 $73K
Total Assets Q1 2015 · Mar 31, 2015 $86K
Total Assets Q1 2015 · Dec 31, 2014 $106K
Sga Expense Q1 2015 · Mar 31, 2015 $191K
Sga Expense Q1 2015 · Mar 31, 2014 $300K
Rd Expense Q1 2015 · Mar 31, 2015 $13K
Rd Expense Q1 2015 · Mar 31, 2014 $118K
Net Income Q1 2015 · Mar 31, 2015 −$276K
Net Income Q1 2015 · Mar 31, 2014 −$485K
Operating Income Q1 2015 · Mar 31, 2015 −$204K
Operating Income Q1 2015 · Mar 31, 2014 −$423K